Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Toll Like Receptor 4 (hToll or CD284 or TLR4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Abstract
Summary
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 40 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Central Nervous System, Respiratory, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Dermatology, Undisclosed, Ear Nose Throat Disorders, Musculoskeletal Disorders and Other Diseases which include indications Coronavirus Disease 2019 (COVID-19), Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Non Alcoholic Fatty Liver Disease (NAFLD), Allergic Rhinitis, Bacterial Sepsis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dengue Fever, Influenza A Virus, H1N1 Subtype Infections, Kidney Fibrosis, Liver Fibrosis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pain, Respiratory Syncytial Virus (RSV) Infections, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Lung Injury, Acute On Chronic Liver Failure (ACLF), Allergic Asthma, Alzheimer's Disease, Atherosclerosis, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Contact Dermatitis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cyst, Drug Addiction, Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Food Allergy, Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Influenzavirus B Infections, Intracerebral Hemorrhage, Kidney Disease (Nephropathy), Low Back Pain, Lung Cancer, Marginal Zone B-cell Lymphoma, Merkel Cell Carcinoma, Migraine, Multiple Sclerosis, Myocardial Infarction, Nasal Congestion, Necrotizing Enterocolitis, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rhinovirus Infections, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer, Unspecified Dermatological Disorders, Unspecified Infectious Diseases, Unspecified Rare Disease and Viral Respiratory Tract Infection.
The latest report Toll Like Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
13therapeutics Inc
Acepre LLC
Akaza Bioscience Ltd
Allodynic Therapeutics LLC
Apollo Therapeutics LLC
AptaTargets SL
Ayuvis Research Inc
Celestial Therapeutics Inc
Douleur Therapeutics Inc
Edesa Biotech Inc
EyeGene Inc
FasCure Therapeutics LLC
Genesen Co Ltd
Immunovo BV (Inactive)
Inimmune Corp
Kupando GmbH
Lubris Biopharma
Merck & Co Inc
Pattern Pharma Inc
Protara Therapeutics Inc
Revelation Biosciences Inc
Soin Therapeutics LLC
TaiwanJ Pharmaceuticals Co Ltd
Vascular Biogenics Ltd
Xalud Therapeutics Inc
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ApTOLL - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVR-48 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
C-34 - Drug Profile
Product Description
Mechanism Of Action
CIA-05 - Drug Profile
Product Description
Mechanism Of Action
CT-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DT-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ECF-843 - Drug Profile
Product Description
Mechanism Of Action
History of Events
G-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GS-200 - Drug Profile
Product Description
Mechanism Of Action
INI-2004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KUP-101 - Drug Profile
Product Description
Mechanism Of Action
naltrexone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
P-13 - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-7 - Drug Profile
Product Description
Mechanism Of Action
P-MAPA - Drug Profile
Product Description
Mechanism Of Action
History of Events
P2PAR-100 - Drug Profile
Product Description
Mechanism Of Action
paridiprubart - Drug Profile
Product Description
Mechanism Of Action
History of Events
PEPA-10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
resatorvid - Drug Profile
Product Description
Mechanism Of Action
History of Events
REVTX-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
REVTx-99 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize TLR4 for Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit TLR2 and TLR4 for Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Chronic Obstructive Pulmonary Disease, Chronic Asthma and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
TARA-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TJC-0133 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VB-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VB-703 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XT-203 - Drug Profile
Product Description
Mechanism Of Action
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 13therapeutics Inc, 2022
Pipeline by Acepre LLC, 2022
Pipeline by Akaza Bioscience Ltd, 2022
Pipeline by Allodynic Therapeutics LLC, 2022
Pipeline by Apollo Therapeutics LLC, 2022
Pipeline by AptaTargets SL, 2022
Pipeline by Ayuvis Research Inc, 2022
Pipeline by Celestial Therapeutics Inc, 2022
Pipeline by Douleur Therapeutics Inc, 2022
Pipeline by Edesa Biotech Inc, 2022
Pipeline by EyeGene Inc, 2022
Pipeline by FasCure Therapeutics LLC, 2022
Pipeline by Genesen Co Ltd, 2022
Pipeline by Immunovo BV (Inactive), 2022
Pipeline by Inimmune Corp, 2022
Pipeline by Kupando GmbH, 2022
Pipeline by Lubris Biopharma, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Pattern Pharma Inc, 2022
Pipeline by Protara Therapeutics Inc, 2022
Pipeline by Revelation Biosciences Inc, 2022
Pipeline by Soin Therapeutics LLC, 2022
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2022
Pipeline by Vascular Biogenics Ltd, 2022
Pipeline by Xalud Therapeutics Inc, 2022
Dormant Products, 2022
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Summary
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 40 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Oncology, Central Nervous System, Respiratory, Immunology, Cardiovascular, Genito Urinary System And Sex Hormones, Dermatology, Undisclosed, Ear Nose Throat Disorders, Musculoskeletal Disorders and Other Diseases which include indications Coronavirus Disease 2019 (COVID-19), Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Non Alcoholic Fatty Liver Disease (NAFLD), Allergic Rhinitis, Bacterial Sepsis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Dengue Fever, Influenza A Virus, H1N1 Subtype Infections, Kidney Fibrosis, Liver Fibrosis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pain, Respiratory Syncytial Virus (RSV) Infections, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Lung Injury, Acute On Chronic Liver Failure (ACLF), Allergic Asthma, Alzheimer's Disease, Atherosclerosis, Bronchopulmonary Dysplasia, Chronic Asthma, Chronic Liver Disease, Chronic Obstructive Pulmonary Disease (COPD), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Contact Dermatitis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cyst, Drug Addiction, Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Food Allergy, Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Influenzavirus B Infections, Intracerebral Hemorrhage, Kidney Disease (Nephropathy), Low Back Pain, Lung Cancer, Marginal Zone B-cell Lymphoma, Merkel Cell Carcinoma, Migraine, Multiple Sclerosis, Myocardial Infarction, Nasal Congestion, Necrotizing Enterocolitis, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Post-Operative Pain, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rhinovirus Infections, Schistosomiasis, Soft Tissue Sarcoma, Unspecified, Unspecified B-Cell Lymphomas, Unspecified Cancer, Unspecified Dermatological Disorders, Unspecified Infectious Diseases, Unspecified Rare Disease and Viral Respiratory Tract Infection.
The latest report Toll Like Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
13therapeutics Inc
Acepre LLC
Akaza Bioscience Ltd
Allodynic Therapeutics LLC
Apollo Therapeutics LLC
AptaTargets SL
Ayuvis Research Inc
Celestial Therapeutics Inc
Douleur Therapeutics Inc
Edesa Biotech Inc
EyeGene Inc
FasCure Therapeutics LLC
Genesen Co Ltd
Immunovo BV (Inactive)
Inimmune Corp
Kupando GmbH
Lubris Biopharma
Merck & Co Inc
Pattern Pharma Inc
Protara Therapeutics Inc
Revelation Biosciences Inc
Soin Therapeutics LLC
TaiwanJ Pharmaceuticals Co Ltd
Vascular Biogenics Ltd
Xalud Therapeutics Inc
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ApTOLL - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVR-48 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
C-34 - Drug Profile
Product Description
Mechanism Of Action
CIA-05 - Drug Profile
Product Description
Mechanism Of Action
CT-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DT-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ECF-843 - Drug Profile
Product Description
Mechanism Of Action
History of Events
G-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GS-200 - Drug Profile
Product Description
Mechanism Of Action
INI-2004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KUP-101 - Drug Profile
Product Description
Mechanism Of Action
naltrexone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
P-13 - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-7 - Drug Profile
Product Description
Mechanism Of Action
P-MAPA - Drug Profile
Product Description
Mechanism Of Action
History of Events
P2PAR-100 - Drug Profile
Product Description
Mechanism Of Action
paridiprubart - Drug Profile
Product Description
Mechanism Of Action
History of Events
PEPA-10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
resatorvid - Drug Profile
Product Description
Mechanism Of Action
History of Events
REVTX-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
REVTx-99 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize TLR4 for Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit TLR2 and TLR4 for Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Chronic Obstructive Pulmonary Disease, Chronic Asthma and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
TARA-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TJC-0133 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VB-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VB-703 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XT-203 - Drug Profile
Product Description
Mechanism Of Action
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 13therapeutics Inc, 2022
Pipeline by Acepre LLC, 2022
Pipeline by Akaza Bioscience Ltd, 2022
Pipeline by Allodynic Therapeutics LLC, 2022
Pipeline by Apollo Therapeutics LLC, 2022
Pipeline by AptaTargets SL, 2022
Pipeline by Ayuvis Research Inc, 2022
Pipeline by Celestial Therapeutics Inc, 2022
Pipeline by Douleur Therapeutics Inc, 2022
Pipeline by Edesa Biotech Inc, 2022
Pipeline by EyeGene Inc, 2022
Pipeline by FasCure Therapeutics LLC, 2022
Pipeline by Genesen Co Ltd, 2022
Pipeline by Immunovo BV (Inactive), 2022
Pipeline by Inimmune Corp, 2022
Pipeline by Kupando GmbH, 2022
Pipeline by Lubris Biopharma, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Pattern Pharma Inc, 2022
Pipeline by Protara Therapeutics Inc, 2022
Pipeline by Revelation Biosciences Inc, 2022
Pipeline by Soin Therapeutics LLC, 2022
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2022
Pipeline by Vascular Biogenics Ltd, 2022
Pipeline by Xalud Therapeutics Inc, 2022
Dormant Products, 2022
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Related Report
